查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1503341

2030 年微射流市場預測：按產品類型、材料、技術、應用、最終用戶和地區進行的全球分析

Microfluidics Market Forecasts to 2030 - Global Analysis By Product Type (Microfluidic-Based Devices, Microfluidic Components and Other Product Types), Material, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球微射流市場規模將達到 256 億美元，預計到 2030 年將達到 593 億美元，預測期內複合年成長率為 15.0%。

微射流工程是一個跨學科領域，涉及微製造設備中微升或納升規模的少量流體的精確控制和操縱。這些設備有時被稱為實驗室晶片系統，整合了流道、閥門、泵浦和感測器等各種組件，以實現流體的精確處理、混合和分析。微射流設備在醫療診斷、疾病檢測、生物標記監測和藥物傳遞方面也發揮著重要作用。微射流所提供的小型化、自動化和多功能性已經徹底改變了科學研究，並有可能在未來對各種行業產生重大影響。

對照護現場(POC) 診斷的需求不斷成長

POC 診斷需要緊湊、高效且經濟高效的解決方案，能夠在患者所在地提供快速、準確的結果，並減少對密集實驗室測試的需求。可以操縱少量液體的微射流技術完美地滿足了這些需求。微射流技術提高了診斷測試的靈敏度和速度，同時允許以攜帶式格式多重分析和整合複雜的測定。這種需求正在推動微射流設備的創新和投資，從而推動實驗室晶片技術和整合診斷平台的進步。因此，微射流市場正在經歷強勁成長。

微射流設計與操作的複雜性

設計微射流系統需要先進的工程和精密製造技術，這是昂貴且耗時的。這種複雜性通常會導致製造成本增加，使得微射流裝置與傳統診斷方法相比在經濟上沒有吸引力。此外，微射流操作的複雜性需要專門的知識和技術，這可能需要大量的培訓並限制普及。此外，將微射流系統整合到現有的實驗室基礎設施中並確保其可靠性和可重複性可能是一項挑戰。

科技的進步與應用的擴展

微加工技術、材料科學和數位技術整合的創新提高了微射流的精度、效率和功能。這些進步使得先進的實驗室晶片系統的開發成為可能，該系統可以高精度、高速度地執行複雜的生化分析。微射流工程在醫療診斷、藥物傳輸、環境監測和食品安全等領域的廣泛應用正在擴大其市場範圍。

法規核准流程漫長而複雜

對醫療設備的嚴格監管要求，尤其是涉及新技術的醫療器械，可能會導致核准時間延長並增加製造商的成本。這種延遲可能會延遲創新微射流解決方案的上市時間，降低競爭力，並阻礙及時獲得先進的診斷和治療方法。此外，應對複雜的監管環境需要大量資源和專業知識，這對於小型企業和新興企業來說尤其具有挑戰性。

COVID-19 的影響

能夠有效處理少量液體的微射流設備對於開發快速照護現場COVID-19 測試至關重要。此次疫情加速了微射流技術的創新和投資，以滿足對可擴展且經濟高效的診斷解決方案的高需求。此外，人們對快速診斷重要性的認知不斷增強，微射流技術的應用範圍已擴展到 COVID-19 之外，並促進其在感染疾病中的廣泛採用。

基於微射流的設備領域預計將在預測期內成為最大的領域

基於微射流的設備預計將在預測期內成長最快，因為它們能夠精確控制少量流體，以實現高通量篩檢、快速診斷和高效的藥物輸送系統。將多種實驗室功能整合到單一晶片上的能力可以降低成本並提高各種應用的便攜性和效率，包括醫療診斷、環境監測和藥物研究。實驗室晶片技術的興起，促進了照護現場快速、準確的測試，就體現了這種影響。

預計矽細分市場在預測期間內複合年成長率最高

由於微加工精度高、堅固性和生物相容性等優異的材料特性，矽細分市場預計在預測期內將表現出最高的複合年成長率。在微射流裝置的製造中使用矽可以創建對於診斷、藥物傳輸和生物研究應用至關重要的複雜且可靠的結構。矽的導熱性和電特性有利於整合感測器和電子元件。然而，基於矽的製造成本高、複雜性高，這會限制可訪問性和擴充性。

比最大的地區

北美擁有完善的醫療保健系統，一般人群擴大採用新療法，該地區人口中感染疾病和慢性病的患病率預計將在預測期內佔據最大的市場佔有率。此外，癌症負擔的增加預計也將推動對微射流工程的需求。例如，2024年1月，美國癌症協會估計，2024年美國將有超過200萬人被診斷出罹患癌症，高於2023年的190萬人。因此，該國癌症發病率的上升預計將推動微射流工程的需求並推動市場成長。

複合年成長率最高的地區：

由於對可攜式和具有成本效益的診斷設備的需求不斷成長、微加工技術的進步以及政府支持該地區研發的舉措，預計亞太地區將在預測期內保持最高的複合年成長率。由於強大的製造能力和對醫療基礎設施的投資，中國、日本和韓國等國家處於市場成長的前沿。此外，學術機構和產業相關人員之間的合作正在推動微射流技術的創新。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球微射流市場：依產品類型

  • 基於微射流的設備
  • 微射流元件
  • 其他產品類型

第6章全球微射流市場：依材料分類

  • 聚合物
    • 聚甲基丙烯酸甲酯（PMMA）
    • 聚二甲基矽氧烷 (PDMS)
  • 玻璃
  • 矽
  • 其他材料

第7章全球微射流市場：依技術分類

  • 微型幫浦
  • 微射流晶片
  • 微型針
  • 微攪拌機
  • 微型閥
  • 其他技術

第8章全球微射流市場：依應用分類

  • 體外診斷（IVD）
  • 藥物發現與臨床診斷
  • 就地檢驗(POCT)
  • 基因組學和蛋白​​質組學
  • 基於細胞的檢測
  • 實驗室晶片和晶片器官
  • 植入式裝置
  • 其他用途

第9章全球微射流市場：依最終用戶分類

  • 醫院和診斷中心
  • 學術研究所
  • 製藥和生物技術公司
  • 其他最終用戶

第10章全球微射流市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Perkinelmer, Inc.
  • Danaher
  • Life Technologies Corporation
  • Bio-Rad Laboratories, Inc.
  • Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Fluidigm Corporation
  • Qiagen NV
  • Thermo Fischer Scientific
  • Biomerieux
  • Cellix Ltd.
  • Elveflow
  • Micronit Micro Technologies BV
  • Standard BioTools
  • UFluidix
  • Emulate Inc.
  • Dolomite Microfluidics
  • Sphere Fluidics Limited
Product Code: SMRC26507

According to Stratistics MRC, the Global Microfluidics Market is accounted for $25.6 billion in 2024 and is expected to reach $59.3 billion by 2030 growing at a CAGR of 15.0% during the forecast period. Microfluidics is a multidisciplinary field that deals with the precise control and manipulation of small volumes of fluids, typically on the microliter or nanoliter scale, within microfabricated devices. These devices, often referred to as lab-on-a-chip systems, integrate various components such as channels, valves, pumps, and sensors, allowing for the precise handling, mixing, and analysis of fluids. Microfluidic devices also play a crucial role in medical diagnostics, enabling the detection of diseases, monitoring of biomarkers, and drug delivery. The miniaturization, automation, and versatility offered by microfluidics have revolutionized scientific research and have the potential to significantly impact various industries in the future.

Market Dynamics:

Driver:

Rising demand for point-of-care (POC) diagnostics

POC diagnostics require compact, efficient, and cost-effective solutions to deliver quick and accurate results at the patient's location, reducing the need for centralized laboratory testing. Microfluidic technologies, with their capability to manipulate small volumes of fluids, perfectly meet these requirements. They enhance the sensitivity and speed of diagnostic tests while enabling multiplexing and integration of complex assays in portable formats. This demand is driving innovations and investments in microfluidic devices, leading to advancements in lab-on-a-chip technologies and integrated diagnostic platforms. As a result, the microfluidics market is experiencing robust growth.

Restraint:

Complexity of microfluidic design and operation

Designing microfluidic systems requires sophisticated engineering and precise fabrication techniques, which can be costly and time-consuming. These complexities often lead to higher production costs, making microfluidic devices less economically attractive compared to traditional diagnostic methods. Additionally, the intricate nature of microfluidic operations demands specialized knowledge and skills, potentially limiting widespread adoption in clinical and research settings due to the necessity for extensive training. Moreover, integrating microfluidic systems with existing laboratory infrastructure and ensuring their reliability and reproducibility can be challenging.

Opportunity:

Technological advancements and expanding applications

Innovations in microfabrication techniques, material sciences, and integration of digital technologies have enhanced the precision, efficiency, and functionality of microfluidic devices. These advancements enable the development of sophisticated lab-on-a-chip systems capable of performing complex biochemical analyses with high accuracy and speed. The expanding applications of microfluidics in areas such as medical diagnostics, drug delivery, environmental monitoring, and food safety are broadening its market scope.

Threat:

Lengthy and complex regulatory approval process

Stringent regulatory requirements for medical devices, particularly those involving new technologies, can lead to prolonged approval timelines and increased costs for manufacturers. These delays can slow down the time-to-market for innovative microfluidic solutions, reducing their competitive advantage and hindering timely access to advanced diagnostics and treatment options. Additionally, navigating the complex regulatory landscape requires substantial resources and expertise, which can be particularly challenging for smaller companies and startups.

Covid-19 Impact

Microfluidic devices, with their ability to process small fluid volumes efficiently, became crucial for developing quick, point-of-care COVID-19 tests. The pandemic accelerated innovations and investments in microfluidic technologies to meet the high demand for scalable and cost-effective diagnostic solutions. Additionally, the heightened awareness of the importance of quick diagnostics has expanded the applications of microfluidics beyond COVID-19, promoting broader adoption in infectious di

The microfluidic-based devices segment is expected to be the largest during the forecast period

The microfluidic-based devices is expected to be the largest during the forecast period as these devices offer precise control over small fluid volumes, enabling high-throughput screening, rapid diagnostics, and efficient drug delivery systems. Their ability to integrate multiple laboratory functions on a single chip reduces costs and enhances portability and efficiency in various applications, including medical diagnostics, environmental monitoring, and pharmaceutical research. The rise of lab-on-a-chip technologies exemplifies this impact, facilitating quick, accurate testing at the point-of-care.

The silicon segment is expected to have the highest CAGR during the forecast period

The silicon segment is expected to have the highest CAGR during the forecast period due to its excellent material properties, including high precision in microfabrication, robustness, and biocompatibility. Silicon's use in manufacturing microfluidic devices enables the creation of intricate and reliable structures essential for applications in diagnostics, drug delivery, and biological research. Its thermal conductivity and electrical properties are beneficial for integrating sensors and electronic components. However, the high cost and complexity of silicon-based fabrication can limit accessibility and scalability.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to factors such as the well-established healthcare system, the higher adoption of novel therapeutics among the general population, and the increasing prevalence of infectious and chronic diseases among the region's population. Moreover the rising burden of cancer is also expected to fuel the demand for microfluidics. For instance, in January 2024, according to the American Cancer Society, it was estimated that more than 2.0 million cancer cases would be diagnosed in the United States in 2024, an increase from 1.9 million cancer cases in 2023. Hence, the country's growing burden of cancer is expected to fuel the demand for microfluidics and favor market growth.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period owing to rising demand for portable and cost-effective diagnostic devices, advancements in microfabrication technologies, and government initiatives supporting research and development in the region. Countries like China, Japan, and South Korea are at the forefront of market growth, fueled by their strong manufacturing capabilities and investments in healthcare infrastructure. Additionally, collaborations between academic institutions and industry players are fostering innovation in microfluidics technology.

Key players in the market

Some of the key players in Microfluidics market include Illumina, Inc., Agilent Technologies, Inc., Perkinelmer, Inc., Danaher, Life Technologies Corporation, Bio-Rad Laboratories, Inc., Hoffmann-La Roche Ltd, Abbott Laboratories, Fluidigm Corporation, Qiagen N.V., Thermo Fischer Scientific, Biomerieux, Cellix Ltd., Elveflow, Micronit Micro Technologies B.V., Standard BioTools, UFluidix, Emulate Inc., Dolomite Microfluidics and Sphere Fluidics Limited

Key Developments:

In June 2024, Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost. XLEAP-SBS chemistry is a faster, higher quality, and more robust sequencing-by-synthesis chemistry that delivers approximately 20% faster turnaround times.

In June 2024, Agilent Announces Cutting-Edge Advances in GC/MS and LC/Q-TOF Technology at ASMS 2024. These instruments exemplify Agilent's unwavering commitment to advancing scientific discovery through innovative instrumentation, significantly shaping the landscape of mass spectrometry.

In January 2024, Illumina expands collaboration with Janssen to advance molecular residual disease cancer test This collaboration will be the first relating to the development of Illumina's novel molecular residual disease (MRD) assay, a whole-genome sequencing.

Product Types Covered:

  • Microfluidic-Based Devices
  • Microfluidic Components
  • Other Product Types

Materials Covered:

  • Polymers
  • Glass
  • Silicon
  • Other Materials

Technologies Covered:

  • Micro Pumps
  • Microfluidic Chips
  • Micro Needles
  • Micro Mixers
  • Micro Valves
  • Other Technologies

Applications Covered:

  • In Vitro Diagnostics (IVD)
  • Drug Discovery & Clinical Diagnostics
  • Point-of-Care Testing (POCT)
  • Genomics & Proteomics
  • Cell-based Assays
  • Lab-on-a-chip & Organs-on-chips
  • Implantable Devices
  • Other Applications

End Users Covered:

  • Hospitals & Diagnostic Centers
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Microfluidics Market, By Product Type

  • 5.1 Introduction
  • 5.2 Microfluidic-Based Devices
  • 5.3 Microfluidic Components
  • 5.4 Other Product Types

6 Global Microfluidics Market, By Material

  • 6.1 Introduction
  • 6.2 Polymers
    • 6.2.1 Polymethyl Methacrylate (PMMA)
    • 6.2.2 Polydimethylsiloxane (PDMS)
  • 6.3 Glass
  • 6.4 Silicon
  • 6.5 Other Materials

7 Global Microfluidics Market, By Technology

  • 7.1 Introduction
  • 7.2 Micro Pumps
  • 7.3 Microfluidic Chips
  • 7.4 Micro Needles
  • 7.5 Micro Mixers
  • 7.6 Micro Valves
  • 7.7 Other Technologies

8 Global Microfluidics Market, By Application

  • 8.1 Introduction
  • 8.2 In Vitro Diagnostics (IVD)
  • 8.3 Drug Discovery & Clinical Diagnostics
  • 8.4 Point-of-Care Testing (POCT)
  • 8.5 Genomics & Proteomics
  • 8.6 Cell-based Assays
  • 8.7 Lab-on-a-chip & Organs-on-chips
  • 8.8 Implantable Devices
  • 8.9 Other Applications

9 Global Microfluidics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Diagnostic Centers
  • 9.3 Academic & Research Institutes
  • 9.4 Pharmaceutical & Biotechnology Companies
  • 9.5 Other End Users

10 Global Microfluidics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Illumina, Inc.
  • 12.2 Agilent Technologies, Inc.
  • 12.3 Perkinelmer, Inc.
  • 12.4 Danaher
  • 12.5 Life Technologies Corporation
  • 12.6 Bio-Rad Laboratories, Inc.
  • 12.7 Hoffmann-La Roche Ltd
  • 12.8 Abbott Laboratories
  • 12.9 Fluidigm Corporation
  • 12.10 Qiagen N.V.
  • 12.11 Thermo Fischer Scientific
  • 12.12 Biomerieux
  • 12.13 Cellix Ltd.
  • 12.14 Elveflow
  • 12.15 Micronit Micro Technologies B.V.
  • 12.16 Standard BioTools
  • 12.17 UFluidix
  • 12.18 Emulate Inc.
  • 12.19 Dolomite Microfluidics
  • 12.20 Sphere Fluidics Limited

List of Tables

  • Table 1 Global Microfluidics Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Microfluidics Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global Microfluidics Market Outlook, By Microfluidic-Based Devices (2022-2030) ($MN)
  • Table 4 Global Microfluidics Market Outlook, By Microfluidic Components (2022-2030) ($MN)
  • Table 5 Global Microfluidics Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 6 Global Microfluidics Market Outlook, By Material (2022-2030) ($MN)
  • Table 7 Global Microfluidics Market Outlook, By Polymers (2022-2030) ($MN)
  • Table 8 Global Microfluidics Market Outlook, By Polymethyl Methacrylate (PMMA) (2022-2030) ($MN)
  • Table 9 Global Microfluidics Market Outlook, By Polydimethylsiloxane (PDMS) (2022-2030) ($MN)
  • Table 10 Global Microfluidics Market Outlook, By Glass (2022-2030) ($MN)
  • Table 11 Global Microfluidics Market Outlook, By Silicon (2022-2030) ($MN)
  • Table 12 Global Microfluidics Market Outlook, By Other Materials (2022-2030) ($MN)
  • Table 13 Global Microfluidics Market Outlook, By Technology (2022-2030) ($MN)
  • Table 14 Global Microfluidics Market Outlook, By Micro Pumps (2022-2030) ($MN)
  • Table 15 Global Microfluidics Market Outlook, By Microfluidic Chips (2022-2030) ($MN)
  • Table 16 Global Microfluidics Market Outlook, By Micro Needles (2022-2030) ($MN)
  • Table 17 Global Microfluidics Market Outlook, By Micro Mixers (2022-2030) ($MN)
  • Table 18 Global Microfluidics Market Outlook, By Micro Valves (2022-2030) ($MN)
  • Table 19 Global Microfluidics Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 20 Global Microfluidics Market Outlook, By Application (2022-2030) ($MN)
  • Table 21 Global Microfluidics Market Outlook, By In Vitro Diagnostics (IVD) (2022-2030) ($MN)
  • Table 22 Global Microfluidics Market Outlook, By Drug Discovery & Clinical Diagnostics (2022-2030) ($MN)
  • Table 23 Global Microfluidics Market Outlook, By Point-of-Care Testing (POCT) (2022-2030) ($MN)
  • Table 24 Global Microfluidics Market Outlook, By Genomics & Proteomics (2022-2030) ($MN)
  • Table 25 Global Microfluidics Market Outlook, By Cell-based Assays (2022-2030) ($MN)
  • Table 26 Global Microfluidics Market Outlook, By Lab-on-a-chip & Organs-on-chips (2022-2030) ($MN)
  • Table 27 Global Microfluidics Market Outlook, By Implantable Devices (2022-2030) ($MN)
  • Table 28 Global Microfluidics Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 29 Global Microfluidics Market Outlook, By End User (2022-2030) ($MN)
  • Table 30 Global Microfluidics Market Outlook, By Hospitals & Diagnostic Centers (2022-2030) ($MN)
  • Table 31 Global Microfluidics Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
  • Table 32 Global Microfluidics Market Outlook, By Pharmaceutical & Biotechnology Companies (2022-2030) ($MN)
  • Table 33 Global Microfluidics Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.